Roxadustat, a breakthrough anemia treatment, is set for further expansion in China as AstraZeneca acquires full rights from FibroGen in a $160 million deal. Originally developed to treat anemia from chronic kidney disease, roxadustat is also being explored for other indications, including thalassemia-related anemia. While the FDA previously rejected roxadustat in the U.S., China has embraced it as a top therapy, and ongoing regulatory reviews could extend its use for chemotherapy-induced anemia. FibroGen, meanwhile, is shifting focus to prostate cancer treatment but has not ruled out reviving roxadustat’s U.S. development.

At Oxydial, we recognize the urgent need for better anemia treatments, especially for rare blood disorders like thalassemia. As research continues, we remain hopeful that roxadustat and other innovative therapies will bring new solutions to patients worldwide.

Read more: https://medcitynews.com/2025/02/astrazeneca-fibrogen-china-roxadustat-anemia-drug-azn-fgen/

#Anemia #Thalassemia #Hematology #Roxadustat #AstraZeneca #FibroGen #RareDiseases #MedicalInnovation #HealthcareNews